New Era of Immune Checkpoints in Advanced Gastric Cancer

Liao H, Wang Y, Li Z, Chen X and Di J*

Qinghai University, Affiliated Hospital, China

^*Correspondance to: Ji Di 

 PDF  Full Text DOI: 10.25107/2474-1647.3555

Abstract

Gastric Cancer (GC) is a common cancer worldwide, and immunotherapy as a new breakthrough has become one of the important anti-tumor treatment modes. Immune Checkpoint Inhibitors (ICI) mainly activates the immune system by blocking PD-1/PD-L1 and CTLA-4, which is one of the main therapeutic approaches in immunotherapy. Currently, clinical trials of immune checkpoint inhibitors have been successfully used as adjunctive therapy for resectable and unresectable in AGC. At the same time, the analysis found that the data of immune checkpoint inhibitors in the Asian population showed a statistically significant overall survival advantage over the Western population. Therefore, this review reviews the recent progress of immunocheckpoint inhibitors in neoadjuvant/ adjuvant therapy for AGC and in the late treatment of unresectable GC, and describes the significant characteristics and broad application prospects of ICI in Asian population.

Keywords

Cite the article

Liao H, Wang Y, Li Z, Chen X, Di J. New Era of Immune Checkpoints in Advanced Gastric Cancer. Clin Surg. 2022; 7: 3555.